炎症性肠病的疾病经济负担分析。
The cost of illness analysis of inflammatory bowel disease.
机构信息
Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran.
出版信息
BMC Gastroenterol. 2023 Jan 19;23(1):21. doi: 10.1186/s12876-023-02648-z.
BACKGROUND
Inflammatory bowel disease (IBD) is a chronic inflammatory condition involving individuals across all age groups. Recent data suggests the increase in the prevalence of IBD and the surge in applying the biologic drugs in which both change the cost of IBD in recent years. Comprehensive assessment of direct and indirect cost profiles associated with IBD in our area is scarce. This study aimed to determine the economic burden of IBD in Iran from a societal perspective, using cost diaries.
METHODS
Patients available on clinic registry and hospital information system (HIS), who were diagnosed with IBD, were invited to take part in this study. Demographic and clinical data, the healthcare resource utilization or cost items, absenteeism for the patients and their caregivers were obtained. The cost of the used resources were derived from national tariffs. The data regarding premature mortality in IBD patients was extracted from HIS. Productivity loss was estimated based on the human capital method. Then, cost date were calculated as mean annual costs per patient.
RESULTS
The cost diaries were obtained from 240 subjects (Ulcerative colitis: n = 168, Crohn's disease, n = 72). The mean annual costs per patient were 1077 US$ (95% CI 900-1253), and 1608 (95% CI 1256, 1960) for the patients with ulcerative colitis and Crohn's disease, respectively. Of the total costs, 58% and 63% were in terms of the indirect costs for the patients with ulcerative colitis and Crohn's disease, respectively. The cost of illness for country was found to be 22,331,079 US$ and 15,183,678 US$ for patients with ulcerative colitis and Crohn's disease, respectively. Highest nationwide economic burden of IBD was found for patients older than 40 years were estimated to be 8,198,519 US$ and 7,120,891 US$, for ulcerative colitis and Crohn's disease, respectively.
CONCLUSION
The medication was found to be the greatest contributor of direct medical costs. Productivity loss in terms of long-term disability and premature mortality were major components of IBD's economic burden in Iran.
背景
炎症性肠病（IBD）是一种累及各年龄段人群的慢性炎症性疾病。最近的数据表明，IBD 的患病率增加，以及生物药物的应用激增，这两者都改变了近年来 IBD 的成本。对我们地区与 IBD 相关的直接和间接成本状况进行全面评估的资料很少。本研究旨在从社会角度确定伊朗 IBD 的经济负担，使用成本日记。
方法
邀请在诊所登记册和医院信息系统（HIS）中登记的 IBD 患者参与本研究。获取人口统计学和临床数据、患者及其照顾者的医疗资源利用或成本项目、缺勤情况。所用资源的成本源自国家关税。IBD 患者的过早死亡率数据从 HIS 中提取。根据人力资本法估算生产力损失。然后，按照每位患者的平均年费用计算成本数据。
结果
从 240 名患者（溃疡性结肠炎：n=168，克罗恩病：n=72）获得了成本日记。每位患者的平均年费用分别为 1077 美元（95%CI 900-1253）和 1608 美元（95%CI 1256-1960），用于溃疡性结肠炎和克罗恩病患者。总费用中，溃疡性结肠炎和克罗恩病患者的间接费用分别占 58%和 63%。国家疾病负担为 2233.1 万美元，溃疡性结肠炎和克罗恩病患者分别为 1518.37 万美元。年龄超过 40 岁的患者是 IBD 患者中经济负担最重的人群，估计为 819.85 万美元和 7120.89 万美元，用于溃疡性结肠炎和克罗恩病。
结论
药物是直接医疗费用的最大贡献者。长期残疾和过早死亡导致的生产力损失是伊朗 IBD 经济负担的主要组成部分。
Zotero 插件